Atlas Analytics · FDA inspections in India
India Human Drugs Trends: FDA inspections, Form 483 rate and top citations
The FDA inspected Indian human drug facilities 339 times in 2025 in the Atlas dataset, and 206 of those inspections (61%) ended with a Form 483. The first half of 2026 brought 100 inspections and 56 Form 483s. 21 CFR 211.192 and 211.22(d) are the most cited sections since January 2025.
Atlas dataset of FDA human drug inspections in India · January 2025 to June 2026 · figures read October 14, 2026
India Human Drugs Trends
339
Inspections in 2025
61%
Ended with a Form 483, 2025
100
Inspections, Jan to Jun 2026
56%
Ended with a Form 483, 2026
FDA inspections in India by month, human drugs
June 2026 may be incomplete while records are published.
Top CFR citations, Jan 2025 to Jun 2026
- 21 CFR 211.192Investigation of discrepancies32
- 21 CFR 211.22(d)Quality unit procedures29
- 21 CFR 211.113(b)Sterile contamination controls17
- 21 CFR 211.160(b)Laboratory controls16
- 21 CFR 211.67(a)Equipment cleaning15
6 more citations and the monthly mix
Top keywords, Jan 2025 to Jun 2026
- Process validation126
- Procedures120
- Data integrity116
- Contamination99
- Investigations94
5 more keywords, including OOS and aseptic processing
Form 483 outcome by month, 2025
In the complete dashboard
Inspections with and without a Form 483 for every month of 2025.
Citations by establishment type
In the complete dashboard
Manufacturers, API makers, testing labs and repackers, compared side by side.
Complete dashboard
Get the full dashboard for your team
This page shows a free window. Share your work email and our team will send access to the complete dashboard, including:
- Every month of 2025, with and without a Form 483
- All 11 top citations and the monthly citation mix
- Top keywords for any date range
- Filters by establishment type
- Inspection history before 2025
How many FDA inspections happen in India
Indian human drug facilities saw 339 FDA inspections in 2025 and 100 in the first half of 2026. February is the busiest month in both years, with 45 inspections in February 2025 and 31 in February 2026. Across all product categories, India received 431 FDA inspections in 2025, the third most outside the US after the EU and China, according to the US FDA inspections analytics page.
The FDA said in 2025 that it would expand unannounced inspections at foreign facilities, which changes how Indian sites prepare. Our guide to the FDA's overseas inspection approach covers what changed.
| Period | Inspections | With a Form 483 | Form 483 rate |
|---|---|---|---|
| 2025 | 339 | 206 | 61% |
| Jan to Jun 2026 | 100 | 56 | 56% |
The most cited sections at Indian drug facilities
Investigations of discrepancies under 21 CFR 211.192 lead the list with 32 citations since January 2025, followed by quality unit procedures under 211.22(d) with 29. Both point at the same weakness: deviations and out of specification results that are not investigated to a root cause, and a quality unit that does not enforce its own procedures.
You can see how these citations land at individual sites on facility pages such as Alembic Pharmaceuticals in Panchmahal, Alkem Laboratories in Baddi and Apitoria Pharma in Pashamylaram.
| Section | What it covers | Citations |
|---|---|---|
| 21 CFR 211.192 | Production record review and investigation of discrepancies | 32 |
| 21 CFR 211.22(d) | Quality control unit responsibilities and procedures | 29 |
| 21 CFR 211.113(b) | Procedures to prevent microbial contamination of sterile products | 17 |
| 21 CFR 211.160(b) | Scientifically sound laboratory controls | 16 |
| 21 CFR 211.67(a) | Equipment cleaning, maintenance and sanitizing | 15 |
What investigators flag: process validation and data integrity
Atlas tags every finding with topic keywords. Process validation, written procedures and data integrity each appear in more than 115 inspections of Indian drug facilities since January 2025. Data integrity findings usually trace back to audit trails and access controls, covered in our piece on ALCOA in digital systems.
| Keyword | Inspections |
|---|---|
| Process validation | 126 |
| Procedures | 120 |
| Data integrity | 116 |
| Contamination | 99 |
| Investigations | 94 |
Frequently asked questions
How many FDA inspections happen in India each year?
The Atlas dataset records 339 FDA inspections of Indian human drug facilities in 2025 and 431 Indian inspections across all product types. The first half of 2026 brought 100 human drug inspections. Every inspected site has a page in the FDA-inspected facilities directory.
What share of FDA inspections in India end with a Form 483?
In 2025, 206 of 339 FDA human drug inspections in India (61%) ended with a Form 483. In the first half of 2026 the share was 56%, with 56 Form 483s from 100 inspections. Our guide on what a Form 483 is explains what happens next.
What are the most common FDA 483 observations at Indian drug facilities?
Since January 2025 the most cited sections are 21 CFR 211.192, investigation of discrepancies, with 32 citations and 211.22(d), quality unit procedures, with 29. Sterile contamination controls, laboratory controls and equipment cleaning complete the top five. Read the observations in the Form 483 database.
Is the FDA doing more unannounced inspections in India?
Yes. In 2025 the FDA said it would expand unannounced inspections at foreign manufacturing facilities, including India, so sites can no longer count on weeks of notice. Our guide to what the FDA checks at foreign contract manufacturers covers how to stay ready.
How do I get the full India inspection data?
Enter your work email in the dashboard above. The full view adds every month of 2025, all 11 top citations, keyword filters for any date range and establishment type, and earlier history. Our team reviews each request and replies by email.

